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Thirteen newly synthesized or resynthesized diamine-platinum(II) complexes were character-
ized, and their cytotoxic activities (IC50) were tested on parental and resistant ovarian cancer
cell lines. They represent models of conjugates between biologically active vectors and cytotoxic
PtII moieties within the “drug targeting and delivery strategy”. Three drugs, routinely employed
in the clinical treatment of cancer, namely, cisplatin, carboplatin, and oxaliplatin, were also
included in the study as controls. The quantitative structure-activity relationship approach
provides simple regression models able to predict log(1/IC50) of diamine-platinum(II) complexes
on both parental and resistant ovarian cancer cell lines. The 16 complexes were characterized
using 197 molecular descriptors, after which the best regression models relating a subset of
these descriptors to the log(1/IC50) in the two cancer cell lines were calculated. Models with
four variables proved to be endowed with very good predictive ability Q2LMO-50% g 85.6%, making
it possible to discard 50% of the molecules from the test set following for cross-validation
procedure. A four-variable regression model also proved effective in predicting the resistance
index RI, Q2LMO-50% ) 84.4%.
Introduction
Cisplatin and its second-generation analogues, car-
boplatin and oxaliplatin, provide good results in the
treatment of solid tumors, especially in testicular,
ovarian, and colon cancer (oxaliplatin only). The ef-
fectiveness of their clinical use, however, is hampered
by their poor ability to select between malignant and
normal cells (resulting in severe side effects) and their
tendency to provoke chemoresistance.
“Drug targeting and delivery” methods in anticancer
chemotherapy rely on agents with selective access to
tumors to deliver drugs to the target. Approaches to
finding such agents often depend on novel design
strategies employing bioactive vectors, such as interca-
lators, amino acids, sugars, bile acids, folates, and
estrogen analogues.1-5 In this last case, the rationale
is that estrogen-specific receptor proteins are expressed
at higher levels in a significant fraction of breast
carcinomas (ER+) than those in normal breast tissue.6-9
Thus, anchoring PtII derivatives to estrogen moieties
could yield a family of anticancer drugs with preferential
access to breast cancer cell nuclei, allowing for signifi-
cant improvement in the therapeutic index. A similar
approach is to label estrogen derivatives with ç-emitting
99mTc-derivatives for use in SPECT.10
An alternative approach takes advantage of the
enhanced permeability of tumor blood vessels and the
inefficient lymphatic drainage in tumors. Macromolecu-
lar diffusion out of blood vessels is facilitated in the
tumor region, so any drug delivered by an agent can
accumulate in the tumor and persist for long periods of
time. This phenomenon is known as the “enhanced
permeability and retention” (EPR) effect.11-13
For this purpose, a coordinating arm linking the Pt
unit to the bioactive or macromolecular carrier is
required (Figure 1a). In general, a suitable arm consists
of a spacer that ends in, or contains, a chelating diamine
functionality (e.g., ethylenediamine or piperazine). In
both the cases, the spacer should preferentially hydro-
lyze at the somewhat lower pH values14-17 typical of
tumor tissue, thus releasing the cytotoxic agent. The
vector can be linked to the arm using one of several
available reactions, all of which require protection of the
NH2 groups (e.g., with di-tert-butyl dicarbonate, t-BOC).
The procedure involves multistep reactions, generally
affording low yields. Thus, the use of tertiary amines is
often preferred because it does not require protection/
deprotection steps. Furthermore, to increase solubility
in water, dicarboxylate anions are often employed
instead of chlorides as leaving groups. However, Cleare
and Hoeschele’s empirical rules18,19 remind us that
substitution of the hydrogen atom in the amine carrier
groups, as well as the replacement of chlorides with
carboxylates as leaving groups, significantly decreases
the cytotoxicity of the active cis-PtII moiety.
To achieve a more rigorously quantitative approach,
we report on the biological behavior of 16 model cis-PtII
complexes in which both the carrier and the leaving
groups have been varied. Cytotoxicity data obtained on
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cultured human ovarian cancer cell lines, namely,
A2780 (parental cell line) and A2780Cp8 (a cisplatin
resistant subline obtained by continuous in vitro expo-
sure to increasing concentrations of the drug),20 were
examined for potential quantitative structure-activity
relationships (QSARs). To the best of our knowledge,
although several QSAR analyses of antitumor organic
agents have been reported,21-24 none concerning the
cytotoxicity of platinum complexes has yet been pub-
lished. The goal of this investigation is to understand,
by using an in vitro model (cultured cells), whether and
how the modification of the prototypal cisplatin molecule
with chelating diamines (useful to link bioactive vectors)
or dicarboxylates (useful to increase water solubility)
is detrimental to the overall cytotoxicity.
Results and Discussion
Chemistry. We used standard procedures to newly
synthesize or resynthesize 13 platinum(II) complexes
with different combinations of carrier and leaving
ligands. The carriers were NH3, ethylenediamine (en),
N,N,N′,N′-tetramethylethylenediamine (tmen), N,N′-
dimethylpiperazine (dmppz), and (1R,2R)-1,2-diami-
nocyclohexane (DACH), and the leaving ligands were
chloride, propanedioato or malonato (mal), 1,1′-cyclo-
butanedicarboxylato (CBDC), ethanedioato or oxalato
(ox); see Table 1 and Figure 2.
The compounds were synthesized according to a
procedure based on Dhara’s method,25-30 i.e., by reacting
K2[PtCl4] with KI to produce K2[PtI4] in solution; the
latter complex reacts with amines to produce the cis-
[Pt(amine)I2] precipitate. This is a good synthon for
obtaining the corresponding chloride or carboxylato
complex. In fact, upon reaction with Ag2SO4 or AgNO3,
cis-[Pt(amine)I2] produces the corresponding diaqua
complex, which reacts with chloride or dicarboxylalate
to yield the final complex.
All of the complexes were examined using ESI-MS,
multinuclear (1H, 13C, 195Pt) NMR spectroscopy, and
Raman spectroscopy. The molecular formula of each
compound was verified by means of the correct isotope
distribution of the quasi-molecular ion peak. ESI-MS
spectra of carboxylato complexes, dissolved in water/
methanol (1:1 v/v), showed the quasi-molecular ion peak
[M + H]+; dichloride complexes dissolved in water/
dimethylsulfoxide (1:1 v/v) were characterized instead
by the main signal attributable to the [M - Cl +
DMSO]+ species.
Reverse phase HPLC was employed to evaluate the
purity of the compounds (g95%).
The 1H and 13C NMR resonances in the complexes
appared in a lower field than that of the corresponding
free ligands, with the atoms closer to the Pt center
usually more strongly affected.27 The methylene protons
of the malonato ligand were not observed in the 1H NMR
spectra in D2O because of the rapid exchange with the
deuterated solvent. This exchange also occurred when
pure malonic acid was dissolved in D2O. The complex-
ation of malonate to PtII further activates H/D ex-
change.31 Interestingly, the free malonic acid 13C spec-
trum did show the signal of the -CD2- moiety (a
quintuplet, ä ) 40.74 ppm, 1JCD ) 20 Hz) under basic
conditions.
The identity of the products was confirmed by 195Pt
NMR spectroscopy. The spectra of cis-PtA2X2 (A )
amine, X2 ) dicarboxylato) complexes were recorded in
Figure 1. Bioactive and macromolecular carriers for the PtII
cytotoxic fragment.
Table 1. Tested PtII Complexes
complexes no.
cis-diamminedichlorideplatinum(II) (cisplatin) 1
cis-diamminemalonatoplatinum(II) 2
cis-diammine(1,1′-cyclobutanedicarboxylato)platinum(II) (carboplatin) 3
cis-dichlorideethylenediamineplatinum(II) 4
cis-ethylenediaminemalonatoplatinum(II) 5
cis-(1,1′-cyclobutanedicarboxylato)ethylenediamineplatinum(II) 6
cis-dichloride(N,N,N′,N′-tetramethylethylenediamine)platinum(II) 7
cis-malonato(N,N,N′,N′-tetramethylethylenediamine)platinum(II) 8
cis-(1,1′-cyclobutanedicarboxylato)(N,N,N′,N′-tetramethylethylenediamine)platinum(II) 9
cis-dichloride(N,N′-dimethylpiperazine)platinum(II) 10
cis-(N,N′-dimethylpiperazine)malonatoplatinum(II) 11
cis-(1,1′-cyclobutanedicarboxylato)(N,N′-dimethylpiperazine)platinum(II) 12
cis-dichloride[(1R,2R)-1,2-diaminocyclohexane]platinum(II) 13
cis-[(1R,2R)-1,2-diaminocyclohexane]oxalatoplatinum(II) (oxaliplatin) 14
cis-[(1R,2R)-1,2-diaminocyclohexane]malonatoplatinum(II) 15
cis-(1,1′-cyclobutanedicarboxylato)[(1R,2R)-1,2-diaminocyclohexane]platinum(II) 16
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D2O and displayed signals between -1700 and -2000
ppm as expected.27 The cis-PtA2Cl2 complexes were
dissolved in DMSO-d6 and exhibited signals between
-2000 and -2400 ppm as previously reported for
similar compounds.32,33
Raman spectroscopy was employed to further char-
acterize the platinum coordination sphere. As reported
in the literature,34-39 Pt-N stretching was seen from
600 to 400 cm-1, whereas Pt-Cl stretching was ob-
served near 350-300 cm-1. Pt-O stretching (500-400
cm-1) and O-Pt-O, N-Pt-N, and Cl-Pt-Cl bending
(e250 cm-1) were not assigned because they are very
weak and difficult to identify.
Cytotoxicity Assays. The cytotoxic properties of all
of the complexes under investigation were evaluated on
the A2780 human ovarian adenocarcinoma cell line and
on its cisplatin-resistant subline (A2780Cp8). The mech-
anisms underlying tumor resistance to cisplatin are
known to be multifactorial and include decreased drug
transport, increased cellular detoxification due to glu-
tathione and metallothioneins, and changes in DNA
repair involving increased nucleotide excision repair
(NER) and loss of mismatch repair (MMR), as well as
alterations in apoptotic cell death pathways;20 in
A2780Cp8 cells, multiple mechanisms were indeed
found to contribute to resistant phenotype.40
Cytotoxicity tests were performed using the MTT
assay, following exposure of the cells to Pt derivatives
for 120 h. The clinically used cisplatin (1), carboplatin
(3), and oxaliplatin (14) were also included in the study
as controls. In all cases, exposure to drug concentrations
ranging between 0 and 500 íM resulted in a dose-
dependent inhibition of cell survival. Table 2 shows the
IC50 values obtained from nonlinear regression analysis
of dose-response data for the compounds tested; these
correspond to drug concentrations achieving half-
maximal inhibition of cell growth.
Parallel experiments based on the analysis of clono-
genic survival following drug exposure for 3 h were also
performed for some of the Pt derivatives, and the results
Figure 2. Sketch of structures of the complexes.
Table 2. IC50 Values for the Tested Compounds
IC50 (íM) m ( SEa
complex A2780 A2780 Cp8 RIb
1 1.37 ( 0.48 45.03 ( 8.76 32.9
2 7.32 ( 0.39 27.93 ( 4.09 3.8
3 7.66 ( 0.72 123.27 ( 2.04 16.1
4 5.55 ( 1.17 117.96 ( 12.20 21.2
5 8.84 ( 2.16 64.84 ( 5.25 7.3
6 9.21 ( 1.03 65.99 ( 6.80 7.2
7 27.24 ( 1.74 126.80 ( 10.08 4.6
8 176.03 ( 8.23 952.20 ( 108.30 5.4
9 135.90 ( 8.07 643.85 ( 67.98 4.7
10 38.86 ( 8.40 100.22 ( 12.99 2.6
11 167.36 ( 27.13 385.98 ( 25.45 2.3
12 167.52 ( 31.57 615.16 ( 23.31 3.7
13 1.03 ( 0.22 8.26 ( 1.79 8.0
14 0.48 ( 0.16 6.62 ( 0.51 12.4
15 2.22 ( 0.42 9.69 ( 1.78 4.4
16 1.52 ( 0.11 3.74 ( 0.48 2.5
a Complex concentrations inhibiting tumor cell growth by 50%.
IC50 value are reported as means of three independent replication
( SE (standard error). b Resistance index RI ) (IC50 A2780 Cp8)/
(IC50 A2780).
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were found to be fairly consistent with those obtained
from the MTT assays (data not shown).
QSAR Analysis. QSAR analysis was performed
using the procedure described in the Experimental
Section. All of the reference regression models (four
descriptors) performed well both in fitting and in
prediction, as demonstrated by the results reported in
Tables 3, 4, and 5. Despite the severe cross-validation
procedure employed (50% of the molecules were elimi-
nated), the predictive capacity of the calculated regres-
sion models obtained proved highly satisfactory.
QSAR. Cytotoxic Activity of PtII Complexes on
A2780 Human Ovarian Cells. Statistical data for the
best regression models of cytotoxic properties exerted
on cultured human ovarian cancer cells for one, two,
three, and four molecular descriptors are summarized
in Table 3. The models were arranged in decreasing
order of their dimensionality.
The best regression models are largely dominated by
the presence of Moran indices of spatial autocorrelation
I(d)w41 differing either in the topological distance d or
in the physicochemical atomic properties w under
consideration (i.e., Sanderson atomic electronegativity
e and atomic polarizability p). The best regression model
with four variables also contains the information de-
scriptor CIC2, known as the complementary information
content of second order index.42 The molecular descrip-
tor nR09 appears in the best two-variable model and
represents the number of nine-membered rings con-
tained in the PtII complexes. On the basis of the
statistics shown in Table 3, we established the four-
variable model as the reference QSAR for the calculation
of the log(1/IC50). The complete regression equation for
this reference model is as follows
PCA was then performed on a data matrix containing
the four molecular descriptors of the selected model in
columns. The two PCs most highly correlated with the
response were PC1 and PC4, accounting for 35.0% and
35.8%, respectively, of the total variability of the
observed response. As the PCs are mutually orthogonal,
any combination of two or more PCs will explain the
total fraction of the response variability given by the
sum of the squared correlation coefficients between each
PC and the response variable. Accordingly, the loading
and score plots shown in Figure 3, obtained by combin-
ing PC1 and PC4, represent the relationships among
the molecular descriptors and the structures of the PtII
complexes to which 70.8% of the observed variability of
the response can be attributed.
Analysis of Figure 3 reveals that molecular descrip-
tors such as I(3)e and I(4)e correlate precisely with the
increase in the cytotoxic activity recorded for compounds
13-16 (PC4). Higher score values along the two PCs
correspond to higher response values; hence, the most
active compounds are those having positive score values
on each PC. Compounds having negative score values
on PC1 and PC4, instead, are less active ones (8-12).
Furthermore, the loadings plot indicates that the rela-
tion of molecular descriptors such as CIC2 and I(3)e to
PC1 is just the opposite of that of I(4)e, even though
their coefficients in the QSAR model have the same sign.
This behavior can be ascribed to the well-known depen-
dency of the MLR coefficients on the correlation struc-
ture of the X variables; with correlated variables, the
role of each variable is impossible to assign on the basis
of the MLR coefficients, and only their joint contribution
to the response can be evaluated. The nature of the
selected molecular descriptors suggests that the cyto-
toxic activity observed in human ovarian cells is mainly
related to the electronic properties of the PtII complexes.
Moreover, analysis of the role of each descriptor in the
QSAR model reveals that an increase in cytotoxic
activity requires an increased fraction of electronegative
atoms in the PtII complexes, allowing optimization of
the difference in electronegativity between atoms sepa-
rated by three and four bonds. Noteworthy, evidence
was clearly given that electronic effects do indeed play
a role in modulating the antitumor activity of platinum-
based drugs.43
QSAR. Cytotoxic Activity of PtII Complexes on
A2780Cp8 Cisplatin-Resistant Human Ovarian
Cells. Statistical data for the best regression models of
cytotoxic properties exerted on A2780Cp8 cells for 1, 2,
Table 3. Molecular Descriptors and Statistical Information for
the Best Regressions of the log(1/IC50) on Human Ovarian
Cancer Cells for the 16 PtII Complexes
model variables Q2LOO/Q2LMO-50% R2 s F
1 CIC2 I(3)e I(4)e I(2)p 0.971/0.920 0.988 0.111 221.7
2 I(3)e I(4)e I(2)p 0.950/0.914 0.972 0.161 137.8
3 nR09 I(2)p 0.897/0.845 0.932 0.241 88.5
4 I(3)p 0.680/0.637 0.761 0.434 44.5
log(1/IC50) (A2780) ) -1.271 + 0.513CIC2 + 3.821I
(3)e + 2.858I(4)e - 4.747I(2)p
Figure 3. Loadings and score plots derived from PCA on the
four molecular descriptors of the proposed QSAR model for
log(1/IC50) (A2780).
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3, and 4 molecular descriptors are summarized in Table
4. The models were arranged in decreasing order of their
dimensionality.
Because of the relevant correlation between the log-
(1/IC50) observed in A2780 cells and the cisplatin
resistant counterparts A2780Cp8 (r ) 0.917), the best
regression models selected (listed in Tables 3 and 4) are
based on quite similar molecular descriptors. The
descriptors c(1)v and c(4)p are Geary indices of spatial
autocorrelation calculated at the topological distances
of 1 and 4, respectively, and weighted by van der Waals
atomic volumes v or atomic polarizabilities p.44 The
definition of Geary indices, when applied to molecular
graphs, is closely related to the definition of the Moran
autocorrelation indices already listed in Table 3. More-
over, the descriptor nR09 appeared in some of the best
regression models for both the responses. However,
there are also some other descriptors listed in the best
regression models for the IC50 values observed in the
cisplatin-resistant cells. A brief description of the mean-
ing of each descriptor is given below.
The molecular descriptor BELe7 is one of the BCUT
descriptors family recommended when searching for
chemical similarity/diversity in large databases45 and
is based on an extension of the Burden approach.46 The
BCUT descriptors are derived from hydrogen-included
molecular graphs and are calculated from the Burden
matrix, which is a modified adjacency matrix where the
diagonal elements are atomic properties, whereas the
off-diagonal elements corresponding to pairs of bonded
atoms are the square roots of conventional bond
orders; all of the other elements are set at 0.001. From
this matrix, the BCUT descriptors are calculated as
an ordered sequence of the highest and lowest
eigenvalues: BELe7 is the lowest eigenvalue n.7 of
the modified Burden matrix whose diagonal ele-
ments correspond to atomic Sanderson electronegativi-
ties.
The molecular descriptor IhB is known as the lopping
centric information index and is defined as the mean
information content derived from the pruning partition
of a molecular graph.47 This descriptor can be classified
in the family of centric indices that were proposed to
quantify the degree of compactness of molecules by
distinguishing between molecular structures organized
differently around their center.
The molecular descriptor TIE is known as the E-state
topological parameter48 and is derived from the number
of bonds and independent rings (cyclomatic number)
in the molecule and the sum over all the adjacency
atoms of the product between their E-state index
values.49
On the basis of the data in Table 4, in this case, too,
we established the four-variable model as the reference
QSAR for calculation of the log(1/IC50). The complete
regression equation for this reference model is as
follows
To facilitate interpretation of the proposed model,
PCA was performed on the matrix with the four molec-
ular descriptors of the model, and the two PCs most
highly correlated with the response were selected for
further analysis.
The loading and score plots derived from PCA are
shown in Figure 4. The plots were obtained by combin-
ing PC2 (88.1% of response variance explained) and PC4
(8.4% of response variance explained), because they
explain 96.5% of the total observed variability of
log(1/IC50).
The loadings plot shows the same distribution of
molecular descriptors observed in Figure 3 even though
different PCs were used to create the plot. The electronic
properties of the PtII complexes proved to be of great
relevance in the determination of their activity in
cisplatin-resistant cells. The loadings plot also shows
that the effect of descriptor BELe7 is essentially nega-
tive although a contrary conclusion can be reached from
the positive coefficient in the regression model; once
again, the correlation among descriptors may lead to
misinterpretation of the descriptor roles. As the two PCs
are positively correlated with the response, PtII com-
plexes having the highest positive score values on both
PCs will be the most active ones (13, 14, 16); instead,
Table 4. Molecular Descriptors and Statistical Information for
the Best Regressions of the log(1/IC50) on Cisplatin Resistant
A2780 Human Ovarian Adenocarcinoma Cells (A2780Cp8) for
the 16 PtII Complexes
model variables Q2LOO/Q2LMO-50% R2 s F
1 TIE IhB c(4)p BELe7 0.947/0.856 0.973 0.144 97.9
2 TIE IhB c(4)p 0.912/0.847 0.953 0.181 80.9
3 c(1)v c(4)p 0.825/0.759 0.884 0.273 49.5
4 nR09 0.592/0.472 0.663 0.448 27.5
Figure 4. Loadings and score plots derived from PCA on the
four molecular descriptors of the proposed QSAR model for
log(1/IC50) (A2780Cp8).
log(1/IC50) (A2780Cp8) ) 0.154 - 0.030TIE -
2.537IhB+ 1.872c(4)p + 1.116BELe7
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PtII complexes having the highest negative score values
on both PCs will be the most inactive ones (8).
QSAR. Modeling the Dependency of the Resis-
tance Index (RI) on the Basis of PtII Complexes
Structures. The resistance index was defined as the
ratio between the IC50 value measured on cisplatin
resistant cells (A2780Cp8) and the parental cells (A2780).
RI values greater than 1 were calculated for all the PtII
complexes, proving the efficacy of the resistance mech-
anisms activated by the cells not only against cisplatin
but also against all the other PtII complexes used in this
study. However, given that these mechanisms have a
certain degree of molecular specificity, their efficacy can
be expected to vary within a series of PtII complexes
according to their structural similarity to or diversity
from cisplatin. We therefore extended our QSAR analy-
ses to this response to discover the nature of the
structural features that distinguish cisplatin resistance
mechanisms.
The statistical data for the best regression models of
RI for 1, 2, 3, and 4 molecular descriptors are sum-
marized in Table 5. The models were arranged in
decreasing order of their dimensionality.
Again, the best regression models contain either
Moran or Geary spatial autocorrelation indices and
some BCUT descriptors, such as the lowest eigenvalues
n.3 weighted by atomic masses BELm3 or by Sanderson
atomic electronegativities BELe3. Moreover, the model
with two variables also contains the highest eigenvalues
n.5 weighted by Sanderson atomic electronegativities.
The best regression model with four variables con-
tains the molecular descriptor J, also known as the
global topological charge index, which is one of the
topological charge indices proposed for the evaluation
of the charge transfer between pairs of atoms and,
therefore, the global charge transfer in the molecule.50,51
On the basis of the statistics shown in Table 5, we
once again proposed the model with four variables as
the reference QSAR for the calculation of the resistance
index. The complete regression equation for this refer-
ence model is as follows
The loadings and scores plots derived from PCA on
the four molecular descriptors are shown in Figure 5.
The plots were obtained by combining PC2 (17.7% of
response variance explained) and PC4 (58.2% of re-
sponse variance explained), and this combination ex-
plains 75.9% of the total observed variability of RI.
In this case, it is important to underline that PC2 is
negatively correlated with the response, whereas the
converse is true for PC4. Consequently, higher values
of c(4)v together with low values of J will minimize the
response. However, PC4 is the most highly correlated
principal component with RI; hence, the molecular
descriptors having high loadings along this axis will
produce a larger effect on the response. In particular,
high values of I(8)p will increase the RI values, whereas
high values of BELe3 will reduce the RI values. The
scores plot clearly shows that cisplatin (1) is the most
diverse compound in the series of PtII complexes; indeed
it is the compound with the highest RI, as expected
given its induction of cellular resistance mechanisms.
From the data in Table 2, one can observe that
complexes 13-16, which produce the electrophilic cis-
[Pt(DACH)(H2O)2]2+ species by aquation, are character-
ized both by high activity (low IC50 values) and by low
cross resistance with cisplatin (low RI values).
Conclusions
Figure 6 shows the effects induced on the IC50 values
for A2780 cells by varying the carrier ligands for any
given leaving group. Figure 7 instead shows the effects
induced by varying the leaving groups for any given
carrier ligand.
In both cases, the trend observed for cytotoxicity
evaluated in vitro confirms Cleare and Hoeschele’s
empirical rules as determined from in vivo experiments;
the presence of NH3 or DACH as carrier groups yielded
the highest cytotoxic effects, whereas chloride and
oxalato proved to be the best leaving groups.
The QSAR approach provides simple regression mod-
els capable of predicting log(1/IC50) of diamine-plati-
num(II) complexes. The four-variable model is able to
Table 5. Molecular Descriptors and Statistical Information for
the Best Regressions of the Resistance Index RI for the 16 PtII
Complexes
model variables Q2LOO/Q2LMO-50% R2 s F
1 I(8)p c(4)v BELe3 J 0.963/0.844 0.981 1.344 141.6
2 I(8)p c(4)v BELe3 0.945/0.691 0.973 1.539 142.7
3 I(6)v BEHe5 0.849/0.725 0.902 2.800 60.0
4 BELm3 0.785/0.578 0.818 3.682 62.9
RI ) 38.833 + 37.794I(8)p - 11.183c(4)v -
16.087BELe3 - 7.7601J
Figure 5. Loadings and score plots derived from PCA on the
four molecular descriptors of the proposed QSAR model for
the resistance index.
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predict the gradual increase of IC50 (i.e., the decrease
of cytotoxic activity) when passing from unsubstituted
cis-dichlorideethylenediamineplatinum(II) (IC50 ) 5.55)
to fully methylated cis-dichloride(N,N,N′,N′-tetrameth-
ylethylenediamine)platinum(II) (IC50 ) 27.24). Interest-
ingly, the methylation on the ethylendiamine chain is
less detrimental than the methylation on terminal
amine functionality for cytotoxicity (i.e., the cis-dichlo-
ride(2-methylethylenediamine)platinum(II) is predicted
to have an IC50 value which is close to the unsubstituted
congener (IC50 ) 4.75)). The present QSAR model
indicates the spacer should be linked to the ethylene-
diamine skeleton in order to obtain PtII complex conju-
gated to biological vectors with a residual high cytotox-
icity (Figure 1b). Unfortunately, this strategy is hindered
from the minor chemical reactivity of -CH2- with
respect to -NH2 functionality. Work is in progress in
our laboratories to synthesize and test such PtII conju-
gate derivatives.
Figure 6. IC50 values for A2780: the effects obtained by
varying the carrier ligands.
Figure 7. IC50 values for A2780: the effects induced by
varying the leaving groups.
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Experimental Section
General Procedures. Platinum(II) complexes were syn-
thesized according to standard procedures and were character-
ized by ESI mass spectrometry,52 HPLC,53 multinuclear NMR,
and Raman spectroscopy. (Supporting Information)
Cytotoxicity Assays. A2780 human ovarian cancer cells
and their cisplatin-resistant counterparts A2780Cp8 (so-called
because of their ability to grow in medium containing 8 íM
cisplatin), developed by chronic exposure of the parent cis-
platin-sensitive line to increasing concentrations of cisplatin,
were obtained from Dr. R. Ozols (Fox Chase Cancer Center,
Philadelphia, PA).20 A2780Cp8 cells differ from the parental
cell line in a number of features that contribute to the resistant
phenotype, including alterations in mismatch and nucleotide
excision DNA repair systems and increased glutathione
levels.20,40,54 Both parental and resistant cell lines were
maintained in RPMI1640 medium (Sigma, Italy) supplemented
with 10% fetal calf serum (Mascia Brunelli, Italy), 2 mM
L-glutamine, and 1% antibiotic mixture (Sigma, Italy) under
standard culture conditions (95% O2/5% CO2 at 37 °C in a
humidified atmosphere). Cell survival following exposure to
the different platinum derivatives was evaluated using the
MTT assay ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide]), which quantifies the number of surviving cells
at a given time after exposure to cytotoxic drugs.55 Briefly, 1
 103 cells/well were plated onto 96-well sterile plates in 100
íL of medium and allowed to grow for 24 h. Platinum
derivatives were dissolved in H2O/DMSO and added to the
wells in 100 íL/well of complete culture medium. The final
concentration range used was 0-500 íM; DMSO final con-
centration never exceeded 0.1%. After 120 h, 50 íL of MTT
solution (2 mg/mL) was added to each well, and plates were
incubated for 3 h at 37 °C. Cell viability was determined by
measuring the absorbance at 570 nm using the universal
microplate reader (Bio-Teck Instruments). All cytotoxicity
experiments were performed three times in quadruplicate. The
cytotoxic effects of the different platinum compounds were
defined as the drug concentrations inhibiting tumor cell growth
by 50% (IC50). IC50 values were calculated based on nonlinear
regression analysis of dose-response data, performed using
Calcusyn software (Biosoft, Cambridge, U.K.).
QSAR. The geometries of the 16 cis-PtII complexes were
fully optimized without symmetry constraints using the
semiempirical quantum-mechanical PM3(tm) Hamiltonian as
implemented in the SPARTAN56 molecular modeling software.
All the minimized structures were confirmed as minima via
harmonic frequency calculations (absence of imaginary fre-
quencies). Furthermore, the three-dimensional structures
obtained of the PtII complexes were used as input for the
DRAGON software,57 which was employed to numerically
encode the topology and geometry of these molecules by
theoretical molecular descriptors. To simplify the analysis, only
the following sets of molecular descriptors were used for each
structure (as listed in the Dragon software): constitutional
descriptors, topological descriptors, walk and path counts
descriptors, connectivity descriptors, information descriptors,
2-D autocorrelation descriptors, edge adjacency descriptors,
BCUT descriptors, topological charge descriptors, and eigen-
value-based descriptors.58 The dimensionality of each descrip-
tor set is shown in Table 6.
Use of all the descriptors led to a rather complex numerical
description of each PtII complex; the descriptors matrix was
therefore filtered as follows to remove redundancy: (a) all
constant descriptors were removed; (b) all descriptors differing
from the others in only one value were excluded due to their
low information content; (c) all descriptors having a correlation
coefficient higher than 0.98 with another descriptor were
removed. After the filter, only 197 molecular descriptors were
retained for use in identifying suitable quantitative structure-
activity relationships.
Cytotoxic activity was expressed as log(1/IC50) to remove the
strong deviation from normality of the original response
variables, whereas the resistance index RI was used as is.
Correlation among all the biological responses under con-
sideration was estimated by multiple linear regression (MLR)
based on the most predictive subset of molecular descriptors.
The search for the best regression models was carried out using
an exhaustive algorithm that examines all the possible de-
scriptor combinations with dimensionality from 1 to 4 and
retains only the five best correlations for each dimension. The
best correlations were selected by using the “leave one out”
cross-validation procedure maximizing the Q2LOO statistic.59
However, following the recommendations for QSAR model-
ing,60 each of the regression models retained was further
validated using a “leave more out” procedure. This allowed
analysis of the intrinsic stability of the models calculated when
a higher level of perturbation, of up to 50% of the data
available (Q2LMO-50%), was applied to the original data set.
Only the most stable regression model for each dimension
examined was then selected and considered as a suitable
quantitative structure-activity relationship. To select a refer-
ence QSAR model for each response, the standard error of
estimates (s) and the coefficient of determination (R2) were
also calculated. All the calculations required in searching for
the best regression models were performed using software
provided by one of us (A.M.).
To interpret the selected QSAR models, a principal compo-
nent analysis (PCA)61 was performed on data matrices con-
structed from the molecular descriptors of the selected models
calculated for the 16 PtII complexes. The two principal com-
ponents (PCs) sharing the highest correlation coefficients with
the response variable were then used to analyze either the
relationships among the molecular descriptors by means of
their loadings or the similarities among the PtII complexes by
means of their scores. PCA was performed on autoscaled data
by using the STATISTICA software.62
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